# Osivax

Canonical: https://abierto.us/vendors/osivax-m4ydkjjrjyc7

- UEI: M4YDKJJRJYC7
- CAGE: FBDR2
- Location: Paris 8, FRA
- Awards in window: 2 (6 transactions), $20,229,361 obligated, July 25, 2025 to September 14, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 2 awards, $20,229,361

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $20,229,361

## Competition

- Full and Open Competition: 2 awards

## Solicitations won

- Clinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strains (75A50125C00008), $98,593,151. https://abierto.us/opportunities/75a50125c00008

## Largest awards

- 75A50125C00008 (definitive contract): $19,485,392, Barda - Aspr / Daappo / Barda DCMA. Osivax - Clinical Proof of Concept of OVX836, a Single-Shot Broadly Protective Influenza a Vaccine for Immediate Protection Against Emerging Pandemic Strains. https://www.usaspending.gov/award/CONT_AWD_75A50125C00008_7505_-NONE-_-NONE-/
- 75A50125C00006 (definitive contract): $743,969, Barda - Aspr / Daappo / Barda DCMA. Oxivax - Aoi #28: Influenza Vaccine Innovation. Advancing Metagenomic Next-Generation Sequencing Based Agnostic Diagnostics for Viral Pathogens the Overall Objective of This Contract Is to Prepare the Ind Package for Ovx836+sq Adjuvant.. https://www.usaspending.gov/award/CONT_AWD_75A50125C00006_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/osivax-m4ydkjjrjyc7.